SGLT2 inhibitors, originally developed as antidiabetic treatments, have demonstrated significant cardiovascular benefits in trials aimed at evaluating their cardiovascular safety in diabetic patients. Since then, researchers have identified multiple additional advantages and proposed various mechanisms to explain these effects. Although the exact mechanisms remain unclear, trial outcomes have consistently shown their effectiveness and revealed potential benefits beyond cardiovascular health. However, there are still adverse effects and certain challenges that limit their prescription. Nevertheless, given their generally well-tolerated profile, substantial benefits, and promising potential, SGLT2 inhibitors represent a valuable treatment option. This thesis provides a brief overview of SGLT2 inhibitors and their use as treatment of congestive heart failure.